JPWO2022009121A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022009121A5 JPWO2022009121A5 JP2023501632A JP2023501632A JPWO2022009121A5 JP WO2022009121 A5 JPWO2022009121 A5 JP WO2022009121A5 JP 2023501632 A JP2023501632 A JP 2023501632A JP 2023501632 A JP2023501632 A JP 2023501632A JP WO2022009121 A5 JPWO2022009121 A5 JP WO2022009121A5
- Authority
- JP
- Japan
- Prior art keywords
- influenza
- cov
- sars
- fragment
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012634 fragment Substances 0.000 claims 37
- 206010022000 influenza Diseases 0.000 claims 28
- 230000002163 immunogen Effects 0.000 claims 26
- 208000025721 COVID-19 Diseases 0.000 claims 13
- 241001678559 COVID-19 virus Species 0.000 claims 12
- 229940001442 combination vaccine Drugs 0.000 claims 11
- 108020001507 fusion proteins Proteins 0.000 claims 11
- 102000037865 fusion proteins Human genes 0.000 claims 11
- 229940096437 Protein S Drugs 0.000 claims 10
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 claims 10
- 101710198474 Spike protein Proteins 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 230000000890 antigenic effect Effects 0.000 claims 9
- 230000009260 cross reactivity Effects 0.000 claims 9
- 101710154606 Hemagglutinin Proteins 0.000 claims 8
- 102000005348 Neuraminidase Human genes 0.000 claims 8
- 108010006232 Neuraminidase Proteins 0.000 claims 8
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims 8
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims 8
- 101710176177 Protein A56 Proteins 0.000 claims 8
- 239000000185 hemagglutinin Substances 0.000 claims 8
- 239000013598 vector Substances 0.000 claims 7
- 210000002845 virion Anatomy 0.000 claims 5
- 108010041986 DNA Vaccines Proteins 0.000 claims 4
- 229940021995 DNA vaccine Drugs 0.000 claims 4
- 229940022005 RNA vaccine Drugs 0.000 claims 4
- 108700021021 mRNA Vaccine Proteins 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 3
- 229960003971 influenza vaccine Drugs 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 230000001932 seasonal effect Effects 0.000 claims 3
- 239000013603 viral vector Substances 0.000 claims 3
- 229940022962 COVID-19 vaccine Drugs 0.000 claims 2
- 101000641175 Human papillomavirus type 18 Major capsid protein L1 Proteins 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 208000002672 hepatitis B Diseases 0.000 claims 2
- 201000010284 hepatitis E Diseases 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 229960001226 live attenuated influenza Drugs 0.000 claims 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 241000991587 Enterovirus C Species 0.000 claims 1
- 101100209954 Human papillomavirus type 16 L1 gene Proteins 0.000 claims 1
- 241000712079 Measles morbillivirus Species 0.000 claims 1
- 241000711386 Mumps virus Species 0.000 claims 1
- 241000710799 Rubella virus Species 0.000 claims 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 241000710772 Yellow fever virus Species 0.000 claims 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229940124740 quadrivalent influenza vaccine Drugs 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 229940031439 squalene Drugs 0.000 claims 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims 1
- 229960000172 trivalent influenza vaccine Drugs 0.000 claims 1
- 229940051021 yellow-fever virus Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2010425.3 | 2020-07-07 | ||
| GB2010425.3A GB2596820A (en) | 2020-07-07 | 2020-07-07 | Combination vaccine |
| PCT/IB2021/056102 WO2022009121A1 (en) | 2020-07-07 | 2021-07-07 | Sars-cov-2 and influenza combination vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023533772A JP2023533772A (ja) | 2023-08-04 |
| JPWO2022009121A5 true JPWO2022009121A5 (enExample) | 2024-07-16 |
Family
ID=72050416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023501632A Pending JP2023533772A (ja) | 2020-07-07 | 2021-07-07 | ＳＡＲＳ－ＣｏＶ－２及びインフルエンザ混合ワクチン |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230256085A1 (enExample) |
| EP (1) | EP4178612A1 (enExample) |
| JP (1) | JP2023533772A (enExample) |
| KR (1) | KR20230049084A (enExample) |
| CN (1) | CN117957016A (enExample) |
| AR (1) | AR122899A1 (enExample) |
| AU (1) | AU2021303789A1 (enExample) |
| BR (1) | BR112023000323A2 (enExample) |
| CA (1) | CA3184878A1 (enExample) |
| CO (1) | CO2023001072A2 (enExample) |
| GB (1) | GB2596820A (enExample) |
| IL (1) | IL299735A (enExample) |
| MX (1) | MX2023000411A (enExample) |
| TW (1) | TW202207979A (enExample) |
| WO (1) | WO2022009121A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10925958B2 (en) | 2016-11-11 | 2021-02-23 | Modernatx, Inc. | Influenza vaccine |
| WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| US11547673B1 (en) | 2020-04-22 | 2023-01-10 | BioNTech SE | Coronavirus vaccine |
| WO2022083768A1 (zh) * | 2020-10-23 | 2022-04-28 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | 免疫原性组合物及其应用 |
| CN113293145B (zh) * | 2021-02-01 | 2022-08-26 | 上海青赛生物科技有限公司 | 一种麻疹病毒活载体新冠疫苗 |
| WO2022221440A1 (en) * | 2021-04-14 | 2022-10-20 | Modernatx, Inc. | Influenza-coronavirus combination vaccines |
| CN113462700B (zh) * | 2021-05-07 | 2023-06-09 | 杨光华 | SARS-CoV-2线性DNA疫苗 |
| CN114717251B (zh) * | 2021-08-24 | 2023-03-24 | 广州恩宝生物医药科技有限公司 | 一种用于预防SARS-CoV-2原始株和Beta株的腺病毒载体疫苗 |
| WO2023047419A1 (en) * | 2021-09-24 | 2023-03-30 | Bharat Biotech International Limited | A vaccine for coronavirus and influenza virus, and method for preparation thereof |
| CN113755644B (zh) * | 2021-09-24 | 2024-05-03 | 中国科学院武汉病毒研究所 | 一种检测新型冠状病毒Alpha和Delta突变体试剂盒及应用 |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| CN114891817A (zh) * | 2022-04-15 | 2022-08-12 | 华南理工大学 | 一种多聚肽及其制备方法与应用 |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
| WO2024174012A1 (pt) * | 2023-02-24 | 2024-08-29 | Instituto Butantan | Composição imunogênica, uso da mesma e processo de obtenção de uma composição imunogênica combinada contra covid-19 e influenza sazonal |
| CN115992101B (zh) * | 2023-03-22 | 2023-07-28 | 深圳市卫光生物制品股份有限公司 | 一种流感病毒裂解疫苗原液的制备方法 |
| CN116327910B (zh) * | 2023-03-31 | 2024-05-03 | 北京吉诺卫生物科技有限公司 | 一种新冠病毒、流感病毒和/或rsv的联合疫苗、其制备方法与应用 |
| CN116350769B (zh) * | 2023-03-31 | 2024-07-19 | 北京吉诺卫生物科技有限公司 | 一种新冠病毒和流感病毒的联合疫苗、其制备方法与应用 |
| EP4710936A1 (en) * | 2023-05-10 | 2026-03-18 | National University Corporation Hokkaido University | Combination vaccine for prevention of influenza and coronavirus infections |
| CN118141906B (zh) * | 2024-02-22 | 2025-08-22 | 安徽智飞龙科马生物制药有限公司 | 一种新冠流感联合疫苗及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| GB9419979D0 (en) * | 1994-10-04 | 1994-11-16 | Medeva Holdings Bv | Vaccine compositions |
| CN1775287A (zh) * | 2004-11-16 | 2006-05-24 | 北京科兴生物制品有限公司 | 一种sars流感二价联合疫苗及其制备工艺 |
| GB0822001D0 (en) * | 2008-12-02 | 2009-01-07 | Glaxosmithkline Biolog Sa | Vaccine |
| BR112013019850B1 (pt) * | 2011-02-04 | 2023-02-28 | Zoetis Services Llc | Composições de vacina e seu uso no tratamento ou prevenção de doenças respiratórias infecciosas caninas |
| GB201108879D0 (en) | 2011-05-25 | 2011-07-06 | Isis Innovation | Vector |
| US20130236494A1 (en) * | 2012-03-06 | 2013-09-12 | Crucell Holland B.V. | Vaccination against influenza |
| CN107961371B (zh) * | 2017-04-19 | 2020-08-11 | 武汉博沃生物科技有限公司 | 季节流感-rsv联合疫苗及其制备方法和应用 |
| CN110974950B (zh) * | 2020-03-05 | 2020-08-07 | 广州恩宝生物医药科技有限公司 | 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗 |
| CN111217917B (zh) * | 2020-02-26 | 2020-10-23 | 康希诺生物股份公司 | 一种新型冠状病毒SARS-CoV-2疫苗及其制备方法 |
| CN111218458B (zh) * | 2020-02-27 | 2020-11-20 | 珠海丽凡达生物技术有限公司 | 编码SARS-CoV-2病毒抗原的mRNA和疫苗及疫苗的制备方法 |
-
2020
- 2020-07-07 GB GB2010425.3A patent/GB2596820A/en not_active Withdrawn
-
2021
- 2021-07-07 KR KR1020237003756A patent/KR20230049084A/ko active Pending
- 2021-07-07 AU AU2021303789A patent/AU2021303789A1/en active Pending
- 2021-07-07 CN CN202180054553.3A patent/CN117957016A/zh active Pending
- 2021-07-07 TW TW110125037A patent/TW202207979A/zh unknown
- 2021-07-07 EP EP21740222.1A patent/EP4178612A1/en active Pending
- 2021-07-07 CA CA3184878A patent/CA3184878A1/en active Pending
- 2021-07-07 IL IL299735A patent/IL299735A/en unknown
- 2021-07-07 AR ARP210101904A patent/AR122899A1/es unknown
- 2021-07-07 WO PCT/IB2021/056102 patent/WO2022009121A1/en not_active Ceased
- 2021-07-07 MX MX2023000411A patent/MX2023000411A/es unknown
- 2021-07-07 JP JP2023501632A patent/JP2023533772A/ja active Pending
- 2021-07-07 BR BR112023000323A patent/BR112023000323A2/pt unknown
- 2021-07-07 US US18/015,025 patent/US20230256085A1/en active Pending
-
2023
- 2023-01-31 CO CONC2023/0001072A patent/CO2023001072A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022009121A5 (enExample) | ||
| US11801297B2 (en) | Vaccine against RSV | |
| Matić et al. | Current view on novel vaccine technologies to combat human infectious diseases | |
| CN111315407B (zh) | 一种广谱抗流感疫苗免疫原及其应用 | |
| CA2722847C (en) | Combined measles-human papilloma vaccine | |
| WO2022083760A1 (zh) | 融合蛋白及其应用 | |
| CN111163800A (zh) | 用于安全诱导针对rsv的免疫的方法 | |
| CN111787982A (zh) | 乙型肝炎免疫方案和组合物 | |
| Gao et al. | A perspective on SARS-CoV-2 virus-like particles vaccines | |
| JP5675789B2 (ja) | 免疫接種のための発現ベクターとしての水疱性口内炎ウイルスの異なる複数の抗原型 | |
| KR20180132742A (ko) | 바이러스 질환을 위한 범용 백신 | |
| CN118787737A (zh) | 乙型肝炎免疫方案和组合物 | |
| Wang et al. | Coronavirus disease-19 vaccine development utilizing promising technology | |
| Karkhanis et al. | Mucosal vaccine vectors: replication-competent versus replication-deficient poxviruses | |
| CN110382518B (zh) | 用于血清型a型口蹄疫病毒的嵌合疫苗 | |
| Srinivas | Recent developments in vaccines strategies against human viral pathogens | |
| JP4797149B2 (ja) | インフルエンザウイルスに対するベクターワクチン | |
| CN119080890A (zh) | H9n2亚型禽流感病毒病毒样颗粒疫苗及其制备方法 | |
| US20040096462A1 (en) | Noval vaccine formulation consisting of dna vaccine and inactivated virus | |
| KR102018602B1 (ko) | Arsntd를 융합파트너로 이용한 수용성 및 활성형 재조합단백질의 생산방법 및 그 생산물 | |
| RU2362586C2 (ru) | Фармацевтические композиции для терапевтического применения | |
| JP2005170945A (ja) | インフルエンザ血球凝集素多価ワクチンの製造方法 | |
| WO2024202045A1 (ja) | 腸管へのウイルス特異的な抗体誘導が可能なノロウイルスワクチン | |
| Norrby | Most of the currently used inactivated rabies vaccine is prepared in | |
| Lin et al. | Research Article Immunogenicity Studies of Bivalent Inactivated Virions of EV71/CVA16 Formulated with Submicron Emulsion Systems |